BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

343 related articles for article (PubMed ID: 37524847)

  • 21. Diffuse midline glioma-H3K27M mutant. A novel entity with a defining and specific IHC marker.
    Agarwal P; Aiyer HM
    Indian J Pathol Microbiol; 2021; 64(2):351-353. PubMed ID: 33851633
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Targeted detection of genetic alterations reveal the prognostic impact of H3K27M and MAPK pathway aberrations in paediatric thalamic glioma.
    Ryall S; Krishnatry R; Arnoldo A; Buczkowicz P; Mistry M; Siddaway R; Ling C; Pajovic S; Yu M; Rubin JB; Hukin J; Steinbok P; Bartels U; Bouffet E; Tabori U; Hawkins C
    Acta Neuropathol Commun; 2016 Aug; 4(1):93. PubMed ID: 27577993
    [TBL] [Abstract][Full Text] [Related]  

  • 23.
    Picca A; Berzero G; Bielle F; Touat M; Savatovsky J; Polivka M; Trisolini E; Meunier S; Schmitt Y; Idbaih A; Hoang-Xuan K; Delattre JY; Mokhtari K; Di Stefano AL; Sanson M
    Neurology; 2018 Jun; 90(23):e2086-e2094. PubMed ID: 29728520
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Spinal intramedullary H3K27M mutant glioma with vertebral metastasis: a case report.
    Handis C; Tanrıkulu B; Danyeli AE; Özek MM
    Childs Nerv Syst; 2021 Dec; 37(12):3933-3937. PubMed ID: 33742289
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prediction of H3K27M mutation status of diffuse midline gliomas using MRI features.
    Chauhan RS; Kulanthaivelu K; Kathrani N; Kotwal A; Bhat MD; Saini J; Prasad C; Chakrabarti D; Santosh V; Uppar AM; Srinivas D
    J Neuroimaging; 2021 Nov; 31(6):1201-1210. PubMed ID: 34189806
    [TBL] [Abstract][Full Text] [Related]  

  • 26. H3F3A K27M mutations in thalamic gliomas from young adult patients.
    Aihara K; Mukasa A; Gotoh K; Saito K; Nagae G; Tsuji S; Tatsuno K; Yamamoto S; Takayanagi S; Narita Y; Shibui S; Aburatani H; Saito N
    Neuro Oncol; 2014 Jan; 16(1):140-6. PubMed ID: 24285547
    [TBL] [Abstract][Full Text] [Related]  

  • 27. High frequency of H3 K27M mutations in adult midline gliomas.
    Ebrahimi A; Skardelly M; Schuhmann MU; Ebinger M; Reuss D; Neumann M; Tabatabai G; Kohlhof-Meinecke P; Schittenhelm J
    J Cancer Res Clin Oncol; 2019 Apr; 145(4):839-850. PubMed ID: 30610375
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The prognostic significance of HIST1H3B/C and H3F3A K27M mutations in diffuse midline gliomas is influenced by patient age.
    Vuong HG; Ngo TNM; Le HT; Dunn IF
    J Neurooncol; 2022 Jul; 158(3):405-412. PubMed ID: 35606633
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Adult diffuse midline gliomas H3 K27-altered: review of a redefined entity.
    López-Pérez CA; Franco-Mojica X; Villanueva-Gaona R; Díaz-Alba A; Rodríguez-Florido MA; Navarro VG
    J Neurooncol; 2022 Jul; 158(3):369-378. PubMed ID: 35567713
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Liquid biopsy in H3K27M diffuse midline glioma.
    Patel J; Aittaleb R; Doherty R; Gera A; Lau B; Messinger D; Wadden J; Franson A; Saratsis A; Koschmann C
    Neuro Oncol; 2024 May; 26(Supplement_2):S101-S109. PubMed ID: 38096156
    [TBL] [Abstract][Full Text] [Related]  

  • 31. H3K27M mutant glioma: Disease definition and biological underpinnings.
    Saratsis AM; Knowles T; Petrovic A; Nazarian J
    Neuro Oncol; 2024 May; 26(Supplement_2):S92-S100. PubMed ID: 37818718
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pediatric midline H3K27M-mutant tumor with disseminated leptomeningeal disease and glioneuronal features: case report and literature review.
    Navarro RE; Golub D; Hill T; McQuinn MW; William C; Zagzag D; Hidalgo ET
    Childs Nerv Syst; 2021 Jul; 37(7):2347-2356. PubMed ID: 32989496
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Harmonization of postmortem donations for pediatric brain tumors and molecular characterization of diffuse midline gliomas.
    Kambhampati M; Panditharatna E; Yadavilli S; Saoud K; Lee S; Eze A; Almira-Suarez MI; Hancock L; Bonner ER; Gittens J; Stampar M; Gaonkar K; Resnick AC; Kline C; Ho CY; Waanders AJ; Georgescu MM; Rance NE; Kim Y; Johnson C; Rood BR; Kilburn LB; Hwang EI; Mueller S; Packer RJ; Bornhorst M; Nazarian J
    Sci Rep; 2020 Jul; 10(1):10954. PubMed ID: 32616776
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Current perspectives on diffuse midline glioma and a different role for the immune microenvironment compared to glioblastoma.
    Pachocki CJ; Hol EM
    J Neuroinflammation; 2022 Nov; 19(1):276. PubMed ID: 36403059
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Molecular Alterations in Pediatric Low-Grade Gliomas That Led to Death.
    Ahrendsen JT; Sinai C; Meredith DM; Malinowski SW; Cooney TM; Bandopadhayay P; Ligon KL; Alexandrescu S
    J Neuropathol Exp Neurol; 2021 Nov; 80(11):1052–1059. PubMed ID: 34580728
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Diffuse midline glioma with H3K27 alteration in adults: a clinicopathological analysis].
    Yang QY; Li MN; Chen TY; Liu C; Li X; Shi ZM; Pan MH
    Zhonghua Bing Li Xue Za Zhi; 2023 Apr; 52(4):376-383. PubMed ID: 36973199
    [No Abstract]   [Full Text] [Related]  

  • 37. [Diffuse midline glioma].
    Saito R
    No Shinkei Geka; 2022 Jan; 50(1):29-38. PubMed ID: 35169084
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Histone-mutant glioma presenting as diffuse leptomeningeal disease.
    Nadkarni T; Hamilton K; Niazi F; Ward M; Okakpu U; Castellani RJ; Prisneac I; Sener U
    CNS Oncol; 2021 Sep; 10(3):CNS75. PubMed ID: 34469205
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Genomic profiling and prognostic factors of H3 K27M-mutant spinal cord diffuse glioma.
    Chai RC; Yan H; An SY; Pang B; Chen HY; Mu QH; Zhang KN; Zhang YW; Liu YQ; Liu X; Zhao Z; Jiang T; Wang YZ; Jia WQ
    Brain Pathol; 2023 Jul; 33(4):e13153. PubMed ID: 36751054
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical Efficacy of ONC201 in H3K27M-Mutant Diffuse Midline Gliomas Is Driven by Disruption of Integrated Metabolic and Epigenetic Pathways.
    Venneti S; Kawakibi AR; Ji S; Waszak SM; Sweha SR; Mota M; Pun M; Deogharkar A; Chung C; Tarapore RS; Ramage S; Chi A; Wen PY; Arrillaga-Romany I; Batchelor TT; Butowski NA; Sumrall A; Shonka N; Harrison RA; de Groot J; Mehta M; Hall MD; Daghistani D; Cloughesy TF; Ellingson BM; Beccaria K; Varlet P; Kim MM; Umemura Y; Garton H; Franson A; Schwartz J; Jain R; Kachman M; Baum H; Burant CF; Mottl SL; Cartaxo RT; John V; Messinger D; Qin T; Peterson E; Sajjakulnukit P; Ravi K; Waugh A; Walling D; Ding Y; Xia Z; Schwendeman A; Hawes D; Yang F; Judkins AR; Wahl D; Lyssiotis CA; de la Nava D; Alonso MM; Eze A; Spitzer J; Schmidt SV; Duchatel RJ; Dun MD; Cain JE; Jiang L; Stopka SA; Baquer G; Regan MS; Filbin MG; Agar NYR; Zhao L; Kumar-Sinha C; Mody R; Chinnaiyan A; Kurokawa R; Pratt D; Yadav VN; Grill J; Kline C; Mueller S; Resnick A; Nazarian J; Allen JE; Odia Y; Gardner SL; Koschmann C
    Cancer Discov; 2023 Nov; 13(11):2370-2393. PubMed ID: 37584601
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.